Gallinella G, Zuffi E, Gentilomi G, Manaresi E, Venturoli S, Bonvicini F, Cricca M, Zerbini M, Musiani M
Division of Microbiology, Department of Clinical and Experimental Medicine, University of Bologna, Italy.
J Med Virol. 2003 Sep;71(1):135-9. doi: 10.1002/jmv.10452.
In order to evaluate the optimal and essential diagnostic test(s) for a correct diagnosis of B19 diseases, 344 consecutive serum samples were tested from 344 patients with clinical suspicion of B19 infection during an epidemic period (early Spring-Autumn 2000). Sera were tested for B19 DNA by a standardized competitive polymerase chain reaction-enzyme-linked immunosorbent assay (PCR-ELISA) and dot-blot hybridization and for specific IgM and IgG by ELISA. Of 344 patients examined, 125 were positive for markers of B19-associated disease: 49 had both B19 DNA and IgM, 50 had B19 DNA without IgM, and 26 had IgM without B19 DNA. After examination of the different patterns of B19 markers as diagnostic tools for B19 infection, IgM determination detected only 60% of B19-documented infections. IgM tests were nevertheless fundamental, as they were the unique diagnostic marker in 20.8% of documented infections (26 of 125 patients), in the diagnosis of recent, but still symptomatic infections when B19 DNA was no longer detectable. The determination of B19 DNA with PCR permitted detection of 79.2% of infections and therefore represented an essential test. PCR was fundamental for the diagnosis of B19 disease, as the unique diagnostic marker in 32% of documented infections (50 of 125 patients), both in acute infections at the onset of symptoms before the appearance of immunological response, and during the course of persistent B19 infections in which IgM had cleared. The contemporaneous determination of B19 DNA by PCR and specific IgM appears to be the most appropriate diagnostic protocol for the correct laboratory diagnosis of B19 infection.
为了评估对B19疾病进行正确诊断的最佳和必要诊断试验,在2000年早春至秋季的流行期间,对344例临床怀疑B19感染的患者的344份连续血清样本进行了检测。通过标准化的竞争性聚合酶链反应-酶联免疫吸附测定(PCR-ELISA)和斑点杂交检测血清中的B19 DNA,并通过ELISA检测特异性IgM和IgG。在344例接受检查的患者中,125例B19相关疾病标志物呈阳性:49例同时有B19 DNA和IgM,50例有B19 DNA但无IgM,26例有IgM但无B19 DNA。在检查不同模式的B19标志物作为B19感染的诊断工具后,IgM测定仅检测到60%的有B19记录的感染。然而,IgM检测仍然至关重要,因为在20.8%的有记录感染(125例患者中的26例)中,它是唯一的诊断标志物,可用于诊断近期但仍有症状的感染,此时B19 DNA已无法检测到。用PCR测定B19 DNA可检测到79.2%的感染,因此是一项必要的检测。PCR对于B19疾病的诊断至关重要,在32%的有记录感染(125例患者中的50例)中,它是唯一的诊断标志物,无论是在症状出现前免疫反应尚未出现的急性感染中,还是在IgM已清除的持续性B19感染过程中。同时通过PCR和特异性IgM测定B19 DNA似乎是对B19感染进行正确实验室诊断的最合适诊断方案。